Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

Fig. 6

Release of angiogenic & inflammatory mediators from DC supernatant: Supernatant from co-culturing TCM and isolated monocyte-derived DCs was collected to determine (a-e) the expression of 7 angiogenic markers using the MSD V-plex angiogenesis and (f-o) expression of 10 inflammatory markers using the MSD V-plex inflammatory panel. The expression level of VEGF-C and TIE-2 were below the level of detection. f Treatment of 1,4-dihydroxy quininib (10 μM) significantly increased (p < 0.05, FC = 1.1) the expression level of IL-13 compared to vehicle control (0.1% DMSO). Statistical analysis was performed using Wilcoxon signed rank test to determine significance between groups, * = p < 0.05. 1,4-dihydrox. Quin. = 1,4-dihydroxy quininib, Bev = Bevacizumab, FC = Fold Change. Error bars represent mean SEM

Back to article page